ICH M9 Draft [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2018-07-16 14:49  – Posting: # 19065
Views: 1,298

Dear all,

on 27 June the ICH released the draft guideline

Biopharmaceutics Classification System-based Biowaivers (M9, step 2).

Public consultation is planned for August 2018 and adoption of the final guideline in May 2019.

I’m wondering how this guideline was developed where one of the founding members of ICH (Japan) does not accept BCS-based biowaivers at all… :confused:


Edit: Deadline for comments:
ANVISA, Brazil - Deadline for comments by 28 January 2019
EC, Europe - Deadline for comments by 6 February 2019
Health Canada, Canada - Deadline for comments by 4 November 2018
HSA, Singapore - Deadline for comments by 26 October 2018
MFDS, Republic of Korea- Deadline for comments by 31 December 2018
MHLW/PMDA, Japan - Deadline for comments by 29 January 2019
NMPA, China - Deadline for comments by 30 November 2018
Swissmedic, Switzerland - Refers to EC, Europe consultation
TFDA, Chinese Taipei - Deadline for comments by 31 October 2018

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
20,619 posts in 4,321 threads, 1,435 registered users;
online 18 (1 registered, 17 guests [including 11 identified bots]).
Forum time: 14:49 CEST (Europe/Vienna)

I have finally come to the konklusion
that a good reliable set ov bowels
iz worth more to a man
than enny quantity of brains.    Josh Billings

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5